Immunohistochemical Expression of Vegf in Renal Cell Carcinoma and Its Correlation with Clinic morphological Features
Keywords:
VEGF, Renal cell carcinoma, ImmunohistochemistryAbstract
INTRODUCTION:Renal Cell Carcinoma (RCC) is the most common renal malignancy in adults, accounting for approximately 90% of kidney cancers. Prognostic and predictive biomarkers play a critical role in understanding RCC progression and guiding targeted therapy. Angiogenesis is a critical step in the growth, invasive progression and metastatic spread of solid tumors. Vascular endothelial growth factor (VEGF) is key regulator of angiogenesis, process of building new blood vessels, which is essential for tumor development and metastasis. Role of VEGF in RCC is not well established.
AIM:The aim of our study was to analyse VEGF expression in different histological variants of RCC and its relationship with histological type, tumor grade, pathological stage, necrosis, lymphovascular invasion, other clinicopathological parameters.
MATERILAS AND METHODS:A retrospective study was performed using paraffin blocks of Renal cell carcinoma reported between 2018 to 2024. For light microscopy screening, sections were initially stained with haematoxylin and eosin stains. In further sections, a primary antibody against VEGF was applied. The level of VEGF expression in renal cell carcinoma was evaluated using a scoring system.
RESULTS:Forty cases with renal cell carcinoma were included. In our study, immunohistochemical positivity showed no significant association with histological type, grade, pathological staging, or lymphovascular invasion (p > 0.05 for all). However, a statistically significant correlation was observed with tumor necrosis (p = 0.015), indicating a potential link between marker expression and necrotic changes in renal cell carcinoma.
CONCLUSION:In this study of renal cell carcinoma, VEGF expression did not significantly vary by histological type, grade, pathological stage, or lymphovascular invasion. However, a significant inverse association was observed between VEGF expression and tumor necrosis (p = 0.015), indicating that reduced VEGF expression is linked to increased tumor necrosis. These findings suggest that VEGF plays a critical role in maintaining vascular integrity within the tumor microenvironment and may have prognostic significance in RCC
Downloads
Metrics
References
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of renal cell carcinoma. European urology. 2019 Jan 1;75(1):74-84.
Birkhäuser FD, Kroeger N, Pantuck AJ. Etiology of renal cell carcinoma: incidence, demographics, and environmental factors. Renal cell carcinoma. 2013:3-22.
Outzen HC, Maguire Jr HC. The etiology of renal-cell carcinoma. InSeminars in Oncology 1983 Dec 1 (Vol. 10, No. 4, pp. 378-384).
Petejova N, Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc. 2016 Jun 1;160(2).
Novacescu D, Feciche BO, Cumpanas AA, Bardan R, Rusmir AV, Bitar YA, Barbos VI, Cut TG, Raica M, Latcu SC. Contemporary clinical definitions, differential diagnosis, and novel predictive tools for renal cell carcinoma. Biomedicines. 2022 Nov 14;10(11):2926.
Sankineni S, Brown A, Cieciera M, Choyke PL, Turkbey B. Imaging of renal cell carcinoma. InUrologic Oncology: Seminars and Original Investigations 2016 Mar 1 (Vol. 34, No. 3, pp. 147-155). Elsevier.
Amin MB, editor. WHO classification of tumours: Urinary and male genital tumours. International Agency for Research on Cancer; 2022.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263
Orczykowski M, Tyszkiewicz M, Rosińska A, Pożarowska K, Miga N. Renal cell carcinoma-epidemiology, risk factors, diagnosis and treatment-review article. Journal of Education, Health and Sport. 2023;13(1):275-80.
Kim E, Zschiedrich S. Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Front Pediatr. 2018 Feb 9;6:16. doi: 10.3389/fped.2018.00016. PMID: 29479523; PMCID: PMC5811471
Albiges L, Salem M, Rini B, Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33.
Rini BI. Vascular endothelial growth factor–targeted therapy in renal cell carcinoma: current status and future directions. Clinical Cancer Research. 2007 Feb 15;13(4):1098-106.
Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer treatment reviews. 2014 May 1;40(4):533-47.
Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye YK, Qin WJ, Zeng GH, Zhu G, Xu CL, Zhong WD. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer investigation. 2009 Jan 1;27(7):788-93.
Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V, ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2012 Oct 1;23:vii65-71.
Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. Journal of the National Cancer Institute. 2013 Dec 18;105(24):1862-70.
Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature reviews Clinical oncology. 2012 Jun;9(6):327-37..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
